Handing over the baton at Gen-Plus: As of October 1st, Tanja Führmann will take over from Dr. Markus Dachtler as CEO of Gen-Plus
Conscio Group is thrilled to announce the appointment of Tanja Führmann as CEO and Managing Director of Gen-Plus. Tanja recently rejoined Gen-Plus from Morphosys, where she served as Global Program Team Director. During her 12-year career at Gen-Plus, she held several key positions including quality control, project management, business development and leading new initiatives. Her career began at Sandoz, where she worked for 11 years as a scientist in the field of transdermal patches and oral films. Markus Dachtler, who took over Gen-Plus in 2015 as part of a management buy-out from Teva / Ratiopharm, successfully developed Gen-Plus into a competent CRDMO with a focus on complex and innovative dosage forms. Following the successful sale to Conscio Group in 2022 and as part of a planned transition process, Markus will step down from his current position on the Executive Board. He will now take on the role of President of Gen-Plus and Strategic Advisor to Conscio Pharma.
We would like to thank Dr Markus Dachtler for successfully driving the growth of Gen-Plus over the past years and look forward to continuing to work with him in his new role.
About Gen-Plus GmbH & Co KG – Pharma innovation for the next generation
The goal of Gen-Plus is the development and research of pharmaceutical innovations for contract partners. The spectrum ranges from the early idea to drug samples (for clinical trials) under GMP conditions and registration batches. With a wide range of diverse technologies and the ability to process highly potent APIs and narcotics, Gen-Plus plans to double in size over the next 3-4 years. In anticipation of growth, the company has recently expanded its facility in Munich. Gen-Plus has also recently become part of the Conscio Group, a network of high-quality scientific service companies with a focus on the pharmaceutical and nutrition industries. As part of this growth story, Gen-Plus will also work closely with the four additional sites within the Conscio Pharma Division, which primarily focus on clinical trials and analytical services.
